Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain. The company has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices. Nutriband Inc. was incorporated in 2016 and is headquartered in Orlando, Florida.
IPO Year:
Exchange: NASDAQ
Website: nutriband.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/22/2025 | $13.00 | Outperform | Noble Capital Markets |
8-K - NutriBand Inc. (0001676047) (Filer)
8-K - NutriBand Inc. (0001676047) (Filer)
EFFECT - NutriBand Inc. (0001676047) (Filer)
POS AM - NutriBand Inc. (0001676047) (Filer)
POS AM - NutriBand Inc. (0001676047) (Filer)
10-Q - NutriBand Inc. (0001676047) (Filer)
10-K/A - NutriBand Inc. (0001676047) (Filer)
10-K - NutriBand Inc. (0001676047) (Filer)
8-K - NutriBand Inc. (0001676047) (Filer)
SCHEDULE 13D - NutriBand Inc. (0001676047) (Subject)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Noble Capital Markets initiated coverage of Nutriband with a rating of Outperform and set a new price target of $13.00
Fastest customizable press release news feed in the world
ORLANDO, Fla., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB) (the "Company") is pleased to announce that it has been invited to present on the Emerging Growth Conference on August 20, 2025. The next Emerging Growth Conference is presenting on August 20, 2025. This live, interactive online event will give existing shareholders and the investment community the opportunity to interact with the Company's Chairman, Serguei Melnik in real time. Mr. Melnik will perform a presentation and may subsequently open the floor for questions. Please submit your questions in advance to [email protected] or ask your questions during the event and Mr. Melnik will do his best to
Sheridan will temporarily step aside as CEO to enter the Irish Presidential Election. Company Chairman and President, Serguei Melnik will take over as interim CEO over the course of the campaign and election period. ORLANDO, Fla., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) has announced that Company CEO, Gareth Sheridan will be stepping aside from his role for three months to enter the Irish Presidential election. The Nomination Hearings followed by the Election will take place over the course of September and October. During this period, Co-Founder and Chairman, Serguei Melnik will take over the responsibilities of CEO and guide th
FDA grants meeting for AVERSA™ FENTANYL (abuse deterrent transdermal system) to provide feedback on the Chemistry, Manufacturing, and Controls plans for the product through commercialization. Nutriband is partnering with Kindeva to develop AVERSA™ FENTANYL which combines Nutriband's AVERSA™ abuse-deterrent technology with Kindeva's FDA-approved fentanyl patch. ORLANDO, Fla., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of prescription transdermal pharmaceutical products, today announced that the United States Food and Drug Administration (US FDA) has granted a Type C Meeting for its lead product, AVERSA™ FENTANYL
ORLANDO, Fla., July 18, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) ("Nutriband" or the "Company") is today reminding shareholders of the key dates associated with its upcoming 25% Preferred stock dividend. Shareholders of record on July 25th 2025 will receive one preferred share for every four shares of common stock held. The pay date for shareholders to receive their new issuance will be August. 5th. Each preferred share will be convertible to one share of common stock following FDA approval of the Company's AVERSA Fentanyl product. If the preferred share remains unconverted it shall be entitled to a cash dividend paid from the profits of the company on an ann
ORLANDO, Fla., July 02, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) ("Nutriband" or the "Company") announced today that its Board of Directors has approved and declared a 25% preferred stock dividend. Shareholders of record on July 25th 2025 will receive one preferred share for every four shares of common stock held. The pay date for shareholders to receive their new issuance will be August 5th. Each preferred share will be convertible to one share of common stock following FDA approval of the Company's AVERSA Fentanyl product. If the preferred share remains unconverted it shall be entitled to a cash dividend paid from the profits of the company on an annual bas
ORLANDO, Fla., July 01, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW), has been added as a member of the Russell Microcap, Russell Microcap Growth, Russell 3000E and Russell 3000E Growth Indexes, as part of the 2025 Russell indexes reconstitution. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes. "Being added to the four Russell indexes is a great honor for us as a company as we continue to strive towards building shareholder value and progressing the development of our AVERSA pipeline and in particular AVERSA Fentanyl which has the potential to reach peak annual US sales of $
Nutriband and Kindeva have completed commercial manufacturing process scale-up for its lead product Aversa™ Fentanyl, an abuse-deterrent fentanyl patch Nutriband is partnering with Kindeva to develop Aversa™ Fentanyl which combines Nutriband's Aversa™ abuse-deterrent technology with Kindeva's FDA-approved fentanyl patch ORLANDO, Fla., June 18, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of prescription transdermal pharmaceutical products, today announced that it has completed commercial manufacturing process scale-up for its lead product, Aversa™ Fentanyl, with Kindeva, a leading global contract development and manufacturing o
Patent issuance expands United States patent coverage for AVERSA™ transdermal abuse deterrent technology AVERSA™ transdermal abuse deterrent technology is protected by a broad international intellectual property portfolio with patents issued in 46 countries including the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia. ORLANDO, Fla., June 09, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of prescription transdermal pharmaceutical products, today announced that the United States Patent and Trademark Office (USPTO) issued patent number 12,318,492 on June 3, 2025, entitled "Abuse and Misuse Deterr
ORLANDO, Fla., June 03, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) today announced that CEO, Gareth Sheridan will present at Noble Capital Markets' Emerging Growth Virtual Equity Conference on Thursday, June 5th at 4PM Eastern Standard Time. The formal presentation will feature a fireside style Q&A session with questions welcome from the live virtual audience. Scheduled 1x1 meetings with the Company are also available for registered, qualified investor attendees. Attendees interested in viewing the live presentation can register for this event, at no cost, here: Virtual Equity Conference Registration A video webcast of the presentation will be available fol
ORLANDO, Fla., June 02, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) reported its financial results for the first quarter ended April 30, 2025. Nutriband is continuing to expand its kinesiology tape output through its Pocono Pharma subsidiary, with a continued focus on penetration pricing to gain a foothold with some of the industry's largest brands. The Company produced a record first quarter reporting revenue of $667,000USD, up 63% % YOY. Pocono manufactured products continue to roll out into prominent retail locations nationwide, including Target, Walmart, Walgreens and CVS and the increasing Pocono revenue stream is key to the company's focus on shareholder v
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - NutriBand Inc. (0001676047) (Issuer)
4 - NutriBand Inc. (0001676047) (Issuer)
4 - NutriBand Inc. (0001676047) (Issuer)
5 - NutriBand Inc. (0001676047) (Issuer)
5 - NutriBand Inc. (0001676047) (Issuer)
5 - NutriBand Inc. (0001676047) (Issuer)
4 - NutriBand Inc. (0001676047) (Issuer)
5/A - NutriBand Inc. (0001676047) (Issuer)
5/A - NutriBand Inc. (0001676047) (Issuer)
4 - NutriBand Inc. (0001676047) (Issuer)
This live feed shows all institutional transactions in real time.
SC 13D/A - NutriBand Inc. (0001676047) (Subject)
SC 13G - NutriBand Inc. (0001676047) (Subject)
SC 13G - NutriBand Inc. (0001676047) (Subject)
SC 13D - NutriBand Inc. (0001676047) (Subject)
Live Leadership Updates
ORLANDO, Fla., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB) (the "Company") is pleased to announce that it has been invited to present on the Emerging Growth Conference on August 20, 2025. The next Emerging Growth Conference is presenting on August 20, 2025. This live, interactive online event will give existing shareholders and the investment community the opportunity to interact with the Company's Chairman, Serguei Melnik in real time. Mr. Melnik will perform a presentation and may subsequently open the floor for questions. Please submit your questions in advance to [email protected] or ask your questions during the event and Mr. Melnik will do his best to
The Glinka family invested $4.5 million into Nutriband through the Company's April 2024 private placementORLANDO, FL / ACCESSWIRE / May 16, 2024 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a developer of transdermal pharmaceutical solutions, today announced the appointment of Sergei Glinka to its board of directors. Glinka is a seasoned and highly respected business executive with an impressive track record in leadership roles across major European companies.Mr. Glinka, an Estonian citizen, is an experienced and highly regarded businessman who has held numerous Executive and Board positions in large European Companies providing Glinka with deep insights and networks across various industri
Live finance-specific insights
ORLANDO, Fla., July 18, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) ("Nutriband" or the "Company") is today reminding shareholders of the key dates associated with its upcoming 25% Preferred stock dividend. Shareholders of record on July 25th 2025 will receive one preferred share for every four shares of common stock held. The pay date for shareholders to receive their new issuance will be August. 5th. Each preferred share will be convertible to one share of common stock following FDA approval of the Company's AVERSA Fentanyl product. If the preferred share remains unconverted it shall be entitled to a cash dividend paid from the profits of the company on an ann
ORLANDO, Fla., July 02, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) ("Nutriband" or the "Company") announced today that its Board of Directors has approved and declared a 25% preferred stock dividend. Shareholders of record on July 25th 2025 will receive one preferred share for every four shares of common stock held. The pay date for shareholders to receive their new issuance will be August 5th. Each preferred share will be convertible to one share of common stock following FDA approval of the Company's AVERSA Fentanyl product. If the preferred share remains unconverted it shall be entitled to a cash dividend paid from the profits of the company on an annual bas
ORLANDO, FL / ACCESSWIRE / May 10, 2024 / RedChip Companies will air interviews with Can-Fite BioPharma Ltd. (NYSE:CANF) and Nutriband Inc. (NASDAQ:NTRB) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, May 11, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Can-Fite: https://www.redchip.com/assets/access/canf_accessNutriband: https://www.redchip.com/assets/access/ntrb_accessIn an exclusive interview, Pnina Fishman, Executive Chairperson and Chief Scientific Officer of Can-Fite BioPharma, appears on the RedChip Small Stocks, Big Money™ show on Blo
Nutriband among the first issuers to dual list on UpstreamORLANDO, FL / ACCESSWIRE / January 5, 2023 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a pioneer in the science of using novel transdermal solutions and other innovative technologies, will become available today at 10:00am EST under the ticker symbol NTRB on Upstream, the revolutionary trading app for digital securities and NFTs powered by Horizon Fintex ("Horizon") and MERJ Exchange Limited ("MERJ"). Nutriband's digital collectible NFT commemorating the dual listing is also available for all Upstream participants to claim with the claim code "NTRB!".Global investors can now trade by downloading Upstream from their preferred app sto
Trading scheduled to Commence on Upstream January 5, 2023ORLANDO, FL / ACCESSWIRE / December 30, 2022 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) announced today that it will be the first company to dual list on Upstream following recent approval."We are proud to have a trailblazer like Nutriband as the first company to dual list on Upstream and offer its shares to an international investor-base seeking streamlined access to U.S. companies," says Upstream Co-Founder Mark Elenowitz.The dual listing on Upstream is designed to provide Nutriband the opportunity to access a global, digital-first investor base that can trade using USDC digital currency along with credit, debit, PayPal, and USD, u
ORLANDO, FL / ACCESSWIRE / December 14, 2022 / RedChip Companies will air a new interview with Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) on The RedChip Money Report® on Bloomberg TV this Saturday, December 17, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Interview highlights:In the exclusive RedChip Money Report interview, Nutriband's Chief Scientific Officer Dr. Jeff Patrick discusses the Company's first-in-class transdermal technology, new CDC guidelines, the technology's application potential, and much more.Access this interview in its entirety at https://www.ntrbinfo.com/interview_accessAbout The RedChip Money Report®The RedChip
ORLANDO, FL / ACCESSWIRE / September 15, 2022 / RedChip Companies will air a new interview with Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), on The RedChip Money Report® on Bloomberg TV, this Saturday, September 17, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Interview highlights:In the exclusive RedChip Money Report interview, Nutriband's Chairman & President Serguei Melnik discusses the Company's expanded patents, near-term commercialization plans, Q2 revenue results, and much more.Access this interview in its entirety at https://www.ntrbinfo.com/interview_accessAbout The RedChip Money Report®The RedChip Money Report® is produced by
ORLANDO, FL / ACCESSWIRE / August 10, 2022 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) ("Nutriband" or the "Company") announced on July 27, 2022 that its Board of Directors had approved and declared a 7:6 forward split of its common stock with a record date of Monday, August 15, 2022 (the "Stock Split"). Each shareholder of record as of the record date will receive one (1) additional share of common stock for each six (6) shares held as of the record date.. No fractional shares of common stock will be issued in connection with the Stock Split. Instead, all fractional shares will be rounded up to the next whole share. The payment date for the Stock Split will be August 25, 2022, and the Comp
ORLANDO, FL / ACCESSWIRE / July 21, 2022 / RedChip Companies will air a new interview with Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), on The RedChip Money Report® on Bloomberg TV, this Saturday, July 23, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Interview highlights:In the exclusive RedChip Money Report interview, Nutriband's CEO Gareth Sheridan discusses the Company's strong revenue growth and partnerships, the Company's solution to the growing opioid crisis, the broad IP portfolio, and much more.Access this interview in its entirety at https://www.ntrbinfo.com/interview_accessAbout The RedChip Money Report®The RedChip Money Repo